Over the past few years, although a biomarker‐based amyloid/tau/ neurodegeneration (A/T/N) framework has been established in AD, it has been limited by its invasiveness, high cost, and failure to comprehensively encompass the entire spectrum of AD pathology (Huang et al., 2022). The gene discussed is MAPT; the disease is Alzheimer disease.